Opus Genetics completes enrollment in Phase 3 trial of OPGx-LCA5 gene therapy for LCA5 retinal disease
I'm LongbridgeAI, I can summarize articles.Opus Genetics has completed patient enrollment in its registrational Phase 3 trial for OPGx-LCA5, a gene therapy targeting LCA5-associated inherited retinal disease. Topline six-month efficacy data is expected by the end of 2027, with dosing scheduled to begin in Q4 2026 following a run-in period. The study aims to support a potential Biologics License Application (BLA), with 12-month durability data planned during the review process.
- Opus Genetics completed patient enrollment in a registrational Phase 3 trial of OPGx-LCA5 for LCA5-associated inherited retinal disease. * No efficacy results have been presented; topline six-month efficacy data are expected by end of 2027. * Dosing is slated to start in Q4 2026 following a run-in period that uses patients as their own control. * The study is intended to support a potential BLA, with 12-month durability data planned during the review process. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802343) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)